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Randomized phase II trial of autologous
dendritic cell vaccines versus autologous
tumor cell vaccines in metastatic
melanoma: 5-year follow up and additional
analyses
Robert O. Dillman1,2*, Andrew N. Cornforth3, Gabriel I. Nistor2, Edward F. McClay4, Thomas T. Amatruda5
and Carol Depriest6

Abstract
Background: Despite improved survival following checkpoint inhibitors, there is still a potential role for anti-cancer
therapeutic vaccines. Because of biological heterogeneity and neoantigens resulting from each patient’s mutanome,
autologous tumor may be the best source of tumor-associated antigens (TAA) for vaccines. Ex vivo loading of
autologous dendritic cells with TAA may be associated with superior clinical outcome compared to injecting
irradiated autologous tumor cells. We conducted a randomized phase II trial to compare autologous tumor cell
vaccines (TCV) and autologous dendritic cell vaccines (DCV) loaded with autologous TAA.
Methods: Short-term autologous tumor cell lines were established from metastatic tumor. Vaccines were admixed
with 500 micrograms of GM-CSF and injected weekly for 3 weeks, then at weeks 8, 12,16, 20, and 24. The primary
endpoint was overall survival. Secondary objectives were identification of adverse events, and results of delayed
type hypersensitivity (DTH) reactions to intradermal tumor cell injections.
Results: Forty-two patients were randomized. All were followed from randomization until death or for five
years; none were lost to follow-up. DCV was associated with longer survival: median 43.4 versus 20.5 months
(95% CI, 18.6 to > 60 versus 9.3 to 32.3 months) and a 70% reduction in the risk of death (hazard ratio = 0.304,
p = 0.0053, 95% CI, 0.131 to 0.702). Tumor DTH reactions were neither prognostic nor predictive. The most
common treatment-related adverse events were mild to moderate local injection site reactions and flu-like
symptoms; but grade 2 treatment-related adverse events were more frequent with TCV. Serum marker analyses
at week-0 and week-4 showed that serum markers were similar at baseline in each arm, but differed after
vaccination.
Conclusions: This is the only human clinical trial comparing DCV and TCV as platforms for autologous TAA
presentation. DCV was associated with minimal toxicity and long-term survival in patients with metastatic
melanoma. DTH to autologous tumor cells was neither prognostic for survival nor predictive of benefit for
either vaccine.
Trial registration: Clinical trials.gov NCT00948480 retrospectively registered 28 July 2009.
Keywords: Metastatic melanoma, Patient-specific vaccines, Dendritic-cell vaccines, Tumor-cell vaccines,
Autologous tumor cell lines
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Background
Relevance of therapeutic vaccine research

During the past decade introduction of new therapies
has been associated with increased survival for patients
with metastatic melanoma [1]. These have included oral
enzyme inhibitors of signal-transduction driver pathways
[2, 3], and monoclonal antibodies that block immune
checkpoint inhibitors [4–6]. However, even with combination checkpoint inhibitors as initial therapy, the 3year survival rates are less than 60% [7]. Therapeutic
vaccines might add to the survival benefit of such patients. First, animal models suggest that anti-tumor vaccines and checkpoint inhibitors are complementary
therapies [8, 9]. Second, the mechanism of action for the
anti-programmed death-1 (PD1) checkpoint inhibitors is
blocking the suppression of an existing immune response, but many patients show no evidence of an existing immune response in their tumors [10, 11]. Third,
therapeutic vaccines have been associated with survival
benefit in some patients [12, 13]. Fourth, dendritic cell
vaccines can induce or enhance immune responses to
patient-specific neoantigens [14]. For these and other
reasons, vaccine research is still relevant for melanoma
treatment [15].
Autologous tumor cells as sources of tumor-associated
antigens

Because of biological heterogeneity and neoantigens
resulting from each mutanome [16, 17], autologous
tumor may be the best source of tumor-associated
antigens (TAA) for vaccines. Short-term tumor cell lines
derived from metastatic lesions is one source of TAA
that could be used for patient-specific vaccines [18, 19].
They can express all TAA, including unique patientspecific TAA expressed only on self-renewing, proliferating autologous tumor cells that may represent tumor
initiating stem cells and/or early progenitor cells. Using
tumor cells from a short-term cell line assures lack of
contamination with viable normal cells or immune
suppressor cells such as regulatory T cells, or myeloid
derived suppressor cells.
Whole tumor cell vaccines versus dendritic cell vaccines

Two potential therapeutic approaches with short-term
tumor cell lines include (1) injecting irradiated tumor cells
(ITC) in a manner similar to many anti-viral vaccines, and
then relying on endogenous antigen-presenting cells to
process TAA and induce anti-tumor immune responses;
and (2) loading antigens from such cells ex vivo into autologous dendritic cells (DC) and vaccinating with these
cells. Patient-specific tumor cell vaccines (TCV) derived
from autologous short-term tumor cell lines were used to
treat 74 metastatic melanoma patients. TCV was welltolerated, associated with an objective response rate (ORR)
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of 9%, progression free survival (PFS) of 4.4 months, and
when all patients were followed to death or for 5 years
from enrollment with none lost to follow-up, median overall survival (OS) was 20.5 months, and 5-year OS 28% [20].
Subsequently 54 metastatic melanoma patients were
treated with patient-specific dendritic cell vaccines (DCV)
consisting of autologous dendritic cells (DC) loaded with
TAA by incubating DC with 10 million ITC derived from
autologous tumor cell lines. DCV was well-tolerated, associated with an ORR of 0%, PFS of 4.2 months, median OS
greater than 5 years, and projected 5-year OS of 54% [21].
When all patients were followed to death or for 5 years
from enrollment with none lost to follow-up, 5-year OS
was 50%.

Significance of current report

A randomized trial (MACVAC) to compare these two
approaches was initiated in October 2007, and is still the
only human trial that has addressed whether a DCV is superior to a TCV. The trial was stopped prematurely due to
discontinuation of financial support by the sponsoring
hospital in April 2011. By then 42 patients had been
randomized; all had initiated treatment per randomization
assignment. Preliminary results were reported at a time
when all patients had completed therapy; so minimum
follow up was six months, median follow up was less than
two years, maximum follow up less than four years, and
21 patients were deceased. OS was better in the DCV arm
with projected 2-year survival rates of 72% versus
31% (p = 0.007) [22]. New information in the current
report includes: (1) survival analysis performed after
all patients had been followed for five years or until
death, (2) details regarding patient characteristics and
treatments administered before and after participation
in this study, (3) results of a multivariate Cox regression analysis and hazards model, (4) survival results
by treatment arm in various subsets of patients, (45)
comparative results of delayed type hypersensitivity
(DTH) reactions to autologous ITC, (6) comparison
of adverse events by treatment arm, (7) comparison
of serum cytokine results before and after vaccination,
(8) and additional analyses regarding the feasibility of
establishing tumor cell lines.

Methods
Design

This was designed as an open-label, randomized trial to
compare autologous DCV to autologous TCV. The primary endpoint was overall survival. Secondary objectives
were identification of adverse events, and results of
delayed type hypersensitivity (DTH) reactions to intradermal tumor cell injections.
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Autologous tumor cell lines

Treatment schedule

Surgically resected metastatic tumors were submitted on
behalf of melanoma patients classified as recurrent stage 3
or distant stage 4. Tumors were mechanically and enzymatically dissociated into single-cell suspensions and
grown in tissue culture as previously described [18, 22, 23].
The patient’s managing physician was notified once a cell
line was successful. These cell cultures were the source of
ITC used for autologous tumor DTH tests, for TCV, and
for co-incubation with DC to create DCV.

At the time of each treatment, a cryopreserved vial of
TCV or DCV was thawed and suspended in 500 micrograms of GM-CSF and injected within five hours of
thawing. Subcutaneous injections were administered
during weeks 1, 2, 3, 8, 12, 16, 20 and 24, as in earlier
trials [21, 22]. Concurrent anti-cancer therapy was not
allowed, but there was a provision by which patients
could interrupt vaccine therapy in order to pursue another therapy because of progressive disease, and then
when that therapy was completed, finish the remaining
vaccine doses.

Autologous dendritic cells

DC were derived from peripheral blood mononuclear cells
obtained during a single leukapheresis procedure and
monocytes were separated (Elutra® Cell Separation System,
CaridianBCT, Lakewood, CO.). Monocytes were differentiated into DC over six days in the presence of granulocytemacrophage colony stimulating factor (GM-CSF) and
interleukin-4 as previously described [21, 22].
Investigational products

TCV consisted of ITC derived from the patient’s autologous tumor cell line as previously described [21–23].
Each dose contained about 10 million ITC.
DCV consisted of autologous DC that were incubated
overnight with 10 million ITC for phagocytosis and antigen loading as previously described [21, 22]. The final
product averaged 10 to 15 million cells per dose, but
ranged from 3 to 30 million per dose among different
patients and included residual ITC in many samples.
There was substantial inter-patient variation in average
dose, but little intra-patient variation in doses.
Patients

Eligibility criteria for the MACVAC trial were previously
described [22]. Key eligibility criteria for randomization
were: (1) availability of short-term autologous tumor cell
line, (2) referral by the managing physician for vaccine therapy, (3) willingness to travel to Newport Beach, California
for treatment, and (4) Karnofsky performance status ≥ 70.
Patients with brain metastases were eligible if they had been
treated with expectation of successful control.
Randomization

Patients were stratified by whether their most advanced
stage of disease was 3 or 4 [24], and by whether they
had measurable disease at the time of randomization
[25]. They were then randomized 1:1 without blocking.
Patients randomized to TCV were able to undergo
DTH testing the next day and start treatment the following week. Patients randomized to DCV underwent a
leukapheresis procedure the same or following day and
could begin DTH testing and treatment about four
weeks later.

Follow up information

After completion of vaccine injections, patients were
followed in person or by telecommunications every three
months to collect information regarding administration
of additional anti-cancer therapies, any new adverse
events (AE) that might be attributable to vaccine treatment, approximate date of disease progression, or date
and cause of death if deceased.
End points

Survival The primary endpoint was OS from the date of
randomization per intent-to treat to date of death. Managing physicians and clinical trial staff identified the first
site of disease progression and a date of disease progression to estimate PFS.
Delayed type hypersensitivity (DTH) to autologous tumor
cells

One week before starting either vaccine, patients were
administered an intradermal skin test of 1 million
ITC. Within 48 to 72 h the test was interpreted by
nursing staff as negative (no induration), weakly positive (5 to 9 mm induration), or positive (≥ 1 cm induration). The test and interpretation was repeated
one week after the three weekly injections had been
administered.
Safety

AE were assessed at each visit for a vaccine injection, and
four weeks after the last injection. AEs and serious AEs
(SAEs) were classified and graded 0 to 5 per National
Cancer Institute Common Toxicity Criteria for Adverse
Events (NCI-CTCAE) version 3.0.
Serum markers

Cryopreserved serum samples (200 μl) from week-0 and
week-4 were sent to Raybiotech, Inc. (Norcross, GA) for
human cytokine protein array screening for the 110
different proteins then available in their Quantibody®
Cytokine Array, which utilizes a validated, quantitative,
multiplex enzyme-linked immunosorbent assay (ELISA).
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In order to normalize the results of various assays,
week-0 and week-4 values for various assays were
expressed as differences above or below the mean values
for three normal controls.

Statistical analysis

Survival curves were generated using the method of
Kaplan and Meier and compared using log rank tests
(Mantel-Haenszel and Gehan’s Wilcoxon). The Cox
regression model and the Wald test were used to
estimate the hazard ratio associated with treatment
and to identify the significance of potential prognostic
factors and their impact on treatment differences.
Variables associated with 3-year survival were explored by multiple univariate analyses. Proportions
were compared using the Pearson Chi Square or
Fisher’s Exact Test. Means were compared using the
Student T-test. Nonparametric means were compared
using the Mann-Whitney test.

Results
Establishing tumor cell lines

As previously reported median time from tissue harvest to
successful cell line was 3.1 months [22], but the range was
from 27 to 224 days. The sites of tumor collection were
lymph nodes (n = 21), cutaneous or subcutaneous tissue
(n = 11), lung (n = 3), breast (n = 2), and one each from
brain, omentum, liver, spleen, and one with multiple sites.
The median tumor weight was 2.3 g (range < 0.2 to
12.5). The cell line success rate was 46/79 (58%) for
tumors ≥ 3 g compared to 30/108 (28%) for those < 3 g
(p < 0.0001) (Additional file 1: Table S1). Among patients for whom cell lines were successful, 42/76 (55%)
were referred for study enrollment. The median time to a
successful cell culture was 81.0 days for both TCV and
DCV; average time was 94.6 days (range17 to 237 days).
There was no correlation between time to establish a cell
line and survival.
Median time from tissue harvest to treatment was
3.0 months (range 3 to 23 months). While efforts
were in progress to establish a cell line, disease progression occurred in 62% of patients who were eventually treated with DCV or TCV (Additional file 2:
Table S2). Among patients with recurrent stage 3 at
the time of tumor tissue acquisition, 9/18 were still
NED at the time of randomization; another who had
developed M1c disease after resection had a complete
response to interleukin-2-based biochemotherapy. The
other eight had progressed to detectable metastatic disease
(7 measurable). Among 24 patients who had distant metastases at the time tissue was collected, only 5 were free
of disease at randomization.
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Treatment assignment, patient characteristics and other
therapies

All patients were treated per randomization assignment
(Additional file 3: Figure S1). Patient baseline characteristics at baseline are shown in Table 1. None of the specific individual characteristics differed significantly
between the arms. There were no differences in therapies given previous or subsequent to DCV or TCV
(Table 2). Patients were treated during November 2007
to August 2011 before widespread use of BRAF/MEK
enzyme inhibitors, and the anti-cytotoxic T lymphocyte4 (CTLA-4) and anti-programmed death-1 (PD-1)
monoclonal antibody checkpoint inhibitors. The first
FDA approvals of these agents were 2010 for ipilimumab, 2011 for vemurafinib, and 2014 for the anti-PD-1
inhibitors pembrolizumab and nivolumab.
Study objectives
Efficacy

DCV was associated with longer OS (Fig. 1a); there was no
increase in PFS (Fig. 1b). A Cox regression analysis
assessed the association between survival and other variables (Additional file 4: Table S3). Only DCV therapy and
tumor burden (defined as measurable, detectable/equivocal
but unmeasurable, or no evidence of disease) were strongly
associated with survival. With the caveat that numbers of
patients in subsets are quite small, for completeness survival by treatment arm for each of various clinical subsets
Table 1 Baseline characteristics of patients and by treatment arm
TCV
(n = 24)

DCV
(N = 18)

P-value

Characteristic

All
(n = 42)

Age ≥ 60 years

20 (48%) 12 (50%) 8 (44%)

# Male

27 (64%) 16 (67%) 11 (61%) 0.71

0.72

# from out of state

16 (38%) 9 (38%)

7 (39%)

0.93

KPS = 100%

21 (50%) 12 (50%) 9 (50%)

1.00

↑LDH at randomization

11 (26%) 4 (17%)

0.16

Highest stage =4

33 (79%) 17 (71%) 16 (89%) 0.16

7 (39%)

Prior brain metastases

10 (24%) 6 (25%)

4 (22%)

1.00

Prior visceral metastases
(non-CNS)

22 (52%) 14 (58%) 8 (44%)

0.45

Measurable Disease

17 (40%) 9 (38%)

8 (44%)

0.65

Detectable (not measurable)

10 (24%) 4 (17%)

6 (33%)

0.28

NED at randomization

15 (36%) 11 (46%) 4 (22%)

0.19

Stage 4 M1a at randomization

3 (7%)

1 (4%)

2 (11%)

0.57

6 (25%)

3 (17%)

0.71

15 (36%) 6 (25%)

9 (50%)

0.094

Stage 4 M1b at randomization 9 (21%)
Stage 4 M1c at randomization

TCV tumor cell vaccine, DCV dendritic cell vaccine, KPS Karnofsky Performance
Status, LDH serum lactate dehydrogenase, CNS central nervous system, NED no
evidence of disease, M1a metastatic disease soft tissue metastases only and
normal LDH, M1b metastatic lung with or without soft tissue metastases, but
no other visceral metastases and normal LDH, M1c metastases to visceral
organs and/or elevated LDH
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Table 2 Anti-melanoma therapy prior and subsequent to
participation in the MACVAC trial. Therapies: overall and by
treatment arm
All
(n = 42)

TCV
(n = 24)

DCV
P-value
(N = 18)

Previous therapy
Surgeries Only

7 (17%)

3 (12%)

4 (22%)

0.44

Radiation Therapy (not brain) 17 (40%) 8 (33%)

9 (50%)

0.28

Brain Radiation Therapy

4 (22%)

1.00

10 (24%) 6 (25%)

Chemotherapy

23 (55%) 15 (62%) 8 (44%)

0.24

Interleukin-2

14 (33%) 8 (33%)

6 (33%)

1.00

IFN-α

20 (48%) 11 (46%) 9 (50%)

0.79

GMCSF

13 (31%) 8 (33%)

5 (28%)

0.70

Anti-VEGF

8 (19%)

4 (17%)

4 (22%)

0.71

Vaccine

5 (12%)

4 (17%)

1 (6%)

0.37

Anti-BRAF

0

0

0

–

Anti-CTLA4

1 (2%)

1 (4%)

0

–

Anti-PD1

0

0

0

–

Subsequent therapy
Metastasectomy

11 (26%) 4 (17%)

7 (39%)

0.16

6 (25%)

3 (17%)

0.71

Brain Radiation Therapy

11 (26%) 6 (25%)

5 (28%)

1.00

Chemotherapy

19 (45%) 11 (46%) 8 (44%)

1.00

Interleukin-2

7 (8%

5 (21%)

2 (11%)

0.68

IFN-α

3 (7%)

2 (8%)

1 (6%)

1.00

GM-CSF

7 (17%)

4 (17%)

3 (17%)

1.00

Anti-VEGF

4 (10%)

2 (8%)

2 (11%)

1.00

Vaccine

1 (2%)

0

1 (6%)

–

Anti-BRAF

7 (17%)

3 (12%)

4 (22%)

0.44

Anti-CTLA4

12 (29%) 7 (29%)

5 (28%)

1.00

Anti-PD1

1 (2%)

0

1 (6%)

0.43

None

9 (21%)

7 (29%)

2 (11%)

0.26

Radiation Therapy (not brain) 9 (21%)

MACVAC melanoma antigen cancer vaccine trial, TCV tumor cell vaccine, DCV
dendritic cell vaccine, IFN-α interferon alpha, GM-CSF granulocyte macrophage
colony stimulating factor, VEGF monoclonal antibody to vascular endothelial
growth factor, BRAF enzyme endcoded by mutated BRAF gene, CTLA4
cytotoxic T Lymphocyte Antigen 4, PD1 programmed death molecule 1

associated with prognostic variables are shown in Table 3.
In an earlier analysis at a time when minimal follow up
was three years, and 17 patients were still in follow up,
treatment in the DCV arm was the only variable associated
with a survival difference. (Additional file 5: Table S4). As
previously reported, there was one delayed complete response in a DCV-treated patient with progressing measurable disease when randomized [26]. At the time of 5-year
follow up, she still had received no other anti-cancer therapy and was still in complete remission. Only one patient
interrupted vaccine treatment to take another therapy, and
then resumed the vaccine. That patient was in the TCV

arm, stopped treatment to receive chemotherapy that he
had received previously, and was still alive after 5 years.
Delayed type hypersensitivity skin test reactivity

Tumor DTH tests were neither prognostic for survival
nor predictive of therapeutic benefit in either arm. There
was no difference between treatment arms in baseline
DTH tests, nor in conversion rate at week-4 from a
negative to positive or weakly positive tumor DTH test
(TCV 5/20 vs DCV 1/17, p = 0.19) (Additional file 6:
Table S5), nor in the rates of ever having a positive
tumor DTH test (TCV 6/22 vs DCV 2/22, p = 0.26).
Safety

Both vaccines were well-tolerated. All eight planned
doses were administered to 67% and 54% of patients in
the DCV and TCV arms respectively. All early discontinuations were due to disease progression; no patients discontinued treatment because of toxicity. The frequencies
of AEs attributed to study agents are summarized in
Table 4. As in previous trials the most common AEs
were injection site reactions and flu-like symptoms and
nearly all treatment-related toxicity was mild to moderate in severity [20, 21]. There was only one grade 3 AE,
a severe headache that occurred after the 8th and final
DCV injection. Toxicity grade was higher in the TCV
arm with 71% of TCV patients experiencing grade 2 or
higher AEs as opposed to only 16% of DCV-treated
patients (17/24 vs 3/18, p = 0.0007) (Table 5).
Serum markers

Paired week-0 and week-4 serum samples were available
for 38 patients. Markers tested included 110 cytokines,
growth factors, proteases, soluble receptors, and other
proteins. Results were grouped together based on known
associations with tumor growth, angiogenesis, and immune activation (Additional file 7: Table S6). At baseline
serum levels of most markers were similar between the
two arms, but tumor markers were higher in the DCV
arm (Fig. 2), consistent with baseline tumor burden
characteristics in that cohort (Table 1). The percent
changes between week-0 and week-4 after the first three
injections of DCV or TCV were quite different (Fig. 2b).
TCV was associated with an increase in nearly all
markers while DCV was associated with a decrease in
several markers. In the TCV arm the tumor and inflammation markers increased from baseline. In the DCV
arm tumor markers were only slightly increased from
baseline, most inflammatory markers decreased from
baseline, and some increased slightly. These results must
be interpreted with caution because of the wide variability in assay results, and the use of only three donors for
normalization.
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Fig. 1 a Overall Survival by treatment arm. Median OS was 43.4 months versus 20.5 months for DCV and TCV respectively (18.6 to > 60 vs 9.3 to
32.3 months, 95% CI) (p = 0.194 Mantel-Haenzsel; p = 0.088 Gehan’s Wilcoxon). Adjusted Cox proportional hazard model revealed a 70% reduction
in risk of death in the DCV arm (HR = 0.304, 95% CI 0.131 to 0.702, p = 0.0053, Wald test). Variables in multivariate analysis included age, stage, LDH,
performance status, gender, M1 category, whether patient had measurable disease, treatment with dendritic cell vaccine, and whether patient lived
outside California (see Additional file 4: Table S3. b Progression free survival (PFS) by treatment arm. Median PFS was 5.4 months in the DCV arm and
3.7 months in the TCV arm (4.0 to 8.0 vs 1.0 to 5.0 months, 95% CI p = 0.498)

Discussion
To our knowledge, this is the first and only study conducted in cancer patients that addresses the question of
whether survival differs between cancer patients treated
with an autologous DCV versus an autologous TCV that
both feature TAA from short-term autologous tumor cell
Table 3 Treatment effects in various subsets
Subset

RX
Arm

#
Pts

Median OS
Months

3-year OS

Measurable

DCV

8

17.6

38%

TCV

9

9.0

11%

Not Measurable

DCV

10

44.6

80%

TCV

15

32.2

33%

Not NED

DCV

14

25.2

50%

TCV

13

9.9

8%

DCV

4

53.0

75%

TCV

11

33.7

40%

DCV

6

17.6

17%

TCV

3

1.1

0%

DCV

11

53.0

82%

TCV

20

21.1

25%

DCV

9

44.6

67%

TCV

12

32.2

33%

DCV

9

38.6

56%

TCV

12

9.0

17%

DCV

16

38.6

56%

TCV

17

16.9

24%

DCV

2

> 60

100%

TCV

7

32.2

29%

NED

High LDH St 4

WNL LDH

KPS =100

KPS < 100

Stage 4

Stage 3

P value
0.122

0.332

0.011

0.561

0.010

0.079

0.810

0.303

0.292

0.141

RX arm treatment arm, Pts patients, OS overall survival, DCV dendritic cell
vaccine, TCV = tumor cell vaccine, NED no evidence of disease, LDH serum
lactate dehydrogenase, St 4 stage 4, KPS Karnofsky Performance Status

lines. The most important observation in this study is
that DCV was associated with a doubling of median OS
and a 70% reduction in the risk of death compared to
TCV. The median survival of 20.5 months in the TCV
arm suggests that TCV may also have anti-tumor activity. The results in each arm of this randomized trial are
quite similar to results previously reported for single
arm trials of TCV [20], and DCV [21]. The lack of
correlation between PFS and OS was also observed in
the earlier trials, and has been observed for other immunotherapies that may provide long-lasting immune
benefit [27]. Examples of FDA-approved agents that improved OS but had unimpressive ORR or PFS include
sipuleucel-T in prostate cancer, [28] and ipilimumab in
melanoma [29].
Table 4 Summary by frequency of AEs of any severity, felt to
possibly, likely, or almost certainly caused by injection of vaccines
Adverse Event

All (N = 42) TCV (n = 24) DCV (n = 18) P value

Injection site reactions 28 (67%)

16 (67%)

12 (67%)

1.00

Flu-like symptoms

14 (33%)

9 (38%)

5 (28%)

0.742

Nausea

8 (19%)

5 (21%)

3 (17%)

1.00

Bone discomfort

7 (17%)

4 (17%)

3 (17%)

1.00

Headache

6 (14%)

3 (12%)

3 (17%)

1.00

Fatigue

5 (12%)

5 (21%)

0 (0%)

0.060

Chills

5 (12%)

1 (4%)

4 (22%)

0.146

Pruritus

3 (7%

2 (8%)

1 (6%)

1.00

Arthralgias

3 (7%)

1 (4%)

2 (11%)

0.567

Fever

3 (7%)

3 (12%)

0 (0%)

0.247

Rash

2 (5%)

2 (8%)

0 (0%)

0.498

Hives (urticarial)

2 (5%)

2 (8%)

0 (0%)

0.498

Shingles

2 (5%)

2 (8%)

0 (0%)

0.498

Myalgias

1 (2%)

0 (0%)

1 (6%)

0.429

TCV tumor cell vaccine, DCV dendritic cell vaccine
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Table 5 Highest grade of adverse events (AEs) felt possibly,
likely or almost certainly caused by injection of vaccine
Grade

All (N = 42)

TCV (n = 24)

DCV (n = 18)

Grade 0

6 (14%)

2 (8%)

4 (22%)

Grade 1

16 (38%)

5 (21%)

11 (61%)

Grade 2

19 (45%)

17 (71%)

2 (11%)

Grade 3

1 (2%)

0

1 (5%)

Grade 4

0

0

0

TCV tumor cell vaccine, DCV dendritic cell vaccine

Strengths of the MACVAC trial include that it was a
randomized trial, all patients received their assigned treatment, all patients were followed until death or for five
years, and no patients were lost to follow up. Patients in
both arms of the study were injected with vaccines that
contained the patient-specific TAA from about 10 million
tumor cells that were self-renewing in cell culture. The
clinical study, including all leukapheresis procedures and
treatment administration took place at a single institution,
but patients were referred from all over the United States
for this trial and remained under the clinical management
of their referring physicians. Weaknesses of this trial are
the small patient numbers, which was caused by the premature closure. Not only did this result in a much smaller
population of subjects than originally planned, but also in
an imbalance in the numbers of patients assigned to each
treatment arm, and some imbalance in baseline prognostic
factors. The imbalance in the treatment arms was due to
the randomization of patients within each stratification,
and the lack of blocking to assure approximately even
randomization at any point in time. The imbalance in
prognostic factors was slightly biased against the DCV
arm. This also resulted in very small numbers of patients
for exploratory subgroup analyses (Table 3), but this data
was presented because of frequent questions from clinical
other investigators regarding outcomes in these subgroups. Double-blinding was not used in this trial because
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it was a phase II trial, and because of the extra cost,
inconvenience, and risks associated with leukapheresis
procedures [30].
DTH tests to autologous tumor could be predictive of
an effective anti-TAA immune response [31, 32]. We
previously reported improved survival for 125 patients
with various cancer histologies who had a positive DTH
at any time during treatment with TCV [33], but this
was not confirmed in TCV-treated metastatic melanoma
patients [20]. There was no association between DTH
reactivity and outcome in DCV-treated melanoma patients in the 54-patient single-arm trial [21]. The MACVAC trial confirmed that this tumor DTH test was not
useful as a predictive or prognostic marker for either
vaccine.
The MACVAC trial confirmed the limited toxicity
associated with these vaccine products in previous trials
[20, 21]. The most common AEs attributed to study injections were local injection site reactions and flu-like
symptoms, which are well-known side effects of GM-CSF.
Interestingly, there was somewhat higher grade toxicity
(grade 2 as opposed to grade 1) in patients receiving TCV.
As part of this trial, serum was obtained at week-0
(baseline) and week-4 (after three weekly injections)
and cryopreserved for later analysis. Comparisons of
baseline samples and changes from week-0 to week-4
after the first three injections showed that the patterns
of changes in cytokine levels differed between DCV
and TCV. This data is included only to address the
question raised by several investigators as to whether
there was any evidence that there was a difference between the study arms in terms of changes in in any
biological measurements after the first three weekly
injections. Much more extensive evaluation would be
needed to better understand the association between
these changes and the clinical benefit observed in the
DCV arm, especially in terms of immune effects on T
cells and their recognition of tumor cells. Such

Fig. 2 a Baseline analysis of serum cytokines. In order to summarize data for all tests, data is expressed as change in relation to values for set of
assays compared to 3 normal control volunteers. There was substantial variation in markers among patients. At baseline most markers were
elevated compared to normals, especially in the DCV arm. b The post treatment analysis of cytokines one week after the third weekly vaccine
injection, showing changes compared to baseline. The changes associated with the two vaccines were quite different. Levels increased for nearly
all markers in the TCV arm, but decreased for eight of the 17 groupings in the DCV arm
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experiments have not been performed because the cell
samples obtained during this trial are no longer the
property of the investigator.
The data regarding success in establishing tumor cell
lines, and the time needed to establish them, is important
for understanding the complex logistics involved in clinical trials of such patient-specific cellular products.
Successful commercial application of autologous tumor
cell lines would likely require a higher and faster rate of
success in obtaining autologous tumor cells as a source of
TAA in order to treat more patients, and to decrease
potential differences in mutations between tumor cells
growing in vitro and tumor cells growing in vivo. The objective of tissue culture was to increase the representation
of self-renewing tumor cells (perhaps early progenitor
cells) as the source of TAA rather than terminally differentiated tumor cells that predominate in a fresh
tumor sample, However, this means that immune responses may be directed against only a small subset of
cells in any tumor mass, which may explain why this
approach is not associated with rapid regression of
measurable tumor.
All attempts to establish dendritic cells were successful. In the DC arm no effort was made to standardize
the number of DC injected, but the range of 3 million
to 30 million cells among patients may be relatively
narrow from a biological perspective. However, theoretically there could have been up to a 100-fold difference
in the density of TAA per DC per patient. The potential
impact of this is unclear given the autologous origin of
the tumor cells and their unique neoantigens. Analyses
failed to show any dose/survival relationship related to
the number of dendritic cells injected among the 18 patients treated in this trial, and among the 54 reported
previously [21].
Since MACVAC was conducted, enzyme-targeted BRAF
inhibitors and monoclonal antibody immune checkpoint
inhibitors, have become standard therapies for patients
with metastatic melanoma, and are associated with improved survival [3, 7] Based on their complementary
mechanisms of action, there is a good rationale for combining vaccines that present autologous TAA with these
newer agents [34, 35]. There is also evidence that such
patient-specific vaccines increase the survival benefit associated with the immune stimulating cytokine interleukin-2
[36]. Ex vivo loading of TAA onto DC outside of the immunosuppressive tumor environment may be especially
advantageous in patients who have normal expression of
major histocompatibility antigens, but have no infiltration
of CD8+ T-lymphocytes in tumor biopsies. Pre-existing
TAA recognition by the endogenous immune system is a
prerequisite for possible benefit from anti-checkpoint
therapy. DCV is worthy of further study combined or
sequenced with these other agents. Other dendritic cell
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vaccines and patient-specific vaccine approaches already
are showing promise in combination with checkpoint
inhibitors [37, 38].

Conclusions
This is the only clinical trial that has compared dendritic
cell and whole tumor cell vaccines as platforms for
autologous TAA presentation. DCV was associated with
superior survival compared to TCV and induced different
changes in serum cytokines than did TCV. DCV was associated with minimal toxicity. As a potential biomarker,
DTH to autologous tumor cells was neither prognostic for
survival nor predictive of benefit from DCV.
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